COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #38 of 230
5/15 Late treatment study
Yu et al., Science China Life Sciences, 2020 May 15, 1-7, doi:10.1007/s11427-020-1732-2 (Peer Reviewed)
Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients With COVID-19
Source   PDF   Share   Tweet
Retrospective, 550 critically ill patients. 19% fatality for HCQ versus 47% for non-HCQ, RR 0.395, p=0.002.
The levels of inflammatory cytokine IL-6 were significantly reduced from 22.2 pg/mL to 5.2 pg/mL (p<0.05) at the end of the treatment in the HCQ group but there was no change in the control group.

Yu et al., 5/15/2020, retrospective, China, Asia, peer-reviewed, 8 authors.
risk of death, 60.5% lower, RR 0.40, p = 0.002, treatment 9 of 48 (18.8%), control 238 of 502 (47.4%).
Details of all 230 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit